News
Read the latest from M8.
Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico

Oct 03, 2022
moksha8 officially rebrands as M8 Pharmaceuticals
May 05, 2022
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico

Oct 05, 2021
M8 Pharmaceuticals Announces License of Exclusive Mexican Rights for Arlevert® from HENNIG ARZNEIMITTEL

Sep 14, 2021
M8 Pharmaceuticals Announces License of Exclusive rights for Diacomit® (Stiripentol) from Biocodex SAS

Aug 31, 2021
M8 Pharmaceuticals Announces License of Exclusive rights MED3000 from Futura Medical for Latin America

Jul 20, 2021
Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America

Jul 06, 2021
Marinomed Biotech AG Grants Exclusive Rights for Carragelose® to M8 Pharmaceuticals marketed locally as Barlo®

Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America
Jul 20, 2021

m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil. This portfolio is comprised of well-known established brands for the treatment of cardiovascular, nervous system, and rheumatological illnesses. The main goal of the partnership is to continue to strengthen the positioning of these products, providing continued support to physicians and ensuring access to the patients in the territory. These original medicines continue to be essential tools in the treatment for their respective indications. This collaboration reinforces m8 Pharmaceuticals' and Pharmanovia's mutual focus to strengthen the presence of their medicines in Latin America, bringing innovative and proven treatments with greater access to patients and caregivers throughout the region.
According to IQVIA, the market size of Latin America's pharmaceutical industry is projected to continue growing in the upcoming years. Currently, Mexico & Brazil makes up about 2/3 of the total pharmaceutical market in Latin America, which is valued at over 45 billion dollars. The portfolio includes Valium®, Rocaltrol®, Inderalici®, Tenormin®, Tenoretic®, Zestril® & Zestoretic®
"We are committed to serve doctors, caregivers and patients by providing them with a holistic portfolio of original market-leading brands and innovative pharmaceuticals. We are delighted to strengthen our strategic partnership with Pharmanovia in the region" said Joel Barlan, m8's CEO.
Regarding the collaboration Amit Patel, Pharmanovia's CEO said "Having had the pleasure of working with the M8 team in the past, we are looking forward to this extended collaboration that strengthens our position in Latin America. We firmly believe our continued partnership will positively impact the benefit of patient health in the territory."
About Pharmanovia – The original medicines specialist globally
Our purpose is to progress iconic medicines for the benefit of patient health globally.
We provide iconic, tried and trusted medicines in the strategic therapeutic areas of Cardiovascular, Women's Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology. We own some of the world's most recognisable brands, including Bonviva®, Inderal®, Kytril®, Naprosyn®, Valium®, Zestril® and more. We operate a portfolio of 20+ brands in 140+ markets with over 200 employees, and we grow through development, licensing and acquisition.
For further information: pharmanovia.com
Pharmanovia Press Contact Kate Antonopoulos, Corporate Marketing & Communications Manager Phone: +44 1268 943857 Katerina.Antonopoulos@pharmanovia.com
For further information, M8 Pharmaceuticals:
Joel Barlan Chief Executive Officer T: +52 (55) 4431 2933 us.wm@moksha8.com
Rafael Ferrer Vice President of Corporate Development T: +1 (305) 299 6998 rafael.ferrer@moksha8.com